CE Information and Faculty Disclosures

• TARGET AUDIENCE
  These activities are intended for medical oncologists, nurses, radiological oncologists and other healthcare providers involved in the treatment of mantle cell lymphoma.
  
  LEARNING OBJECTIVES

  • Develop an understanding of published research with Bruton tyrosine kinase (BTK) inhibitors as a component of front-line treatment for mantle cell lymphoma (MCL), and assess the current and potential roles of this therapeutic approach.
  • Appreciate the biological rationale for, available data with and current indications for the use of covalent BTK inhibitors for relapsed/refractory MCL, and discern how these agents can be appropriately and safely integrated into routine practice.
  • Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for MCL, and identify patients appropriate for treatment with this novel therapeutic strategy.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with covalent and noncovalent BTK inhibitors employed in the management of MCL.
  • Recall investigational therapeutic strategies and ongoing clinical trials attempting to further leverage the benefits of BTK inhibitors for the treatment of MCL.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  Presentations Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Michael Wang, MD
  Puddin Clarke Endowed Professor
  Director, Mantle Cell Lymphoma Program of Excellence
  Section Chief, Rare Lymphomas
  Co-PI, B-Cell Lymphoma Moonshot Project
  Department of Lymphoma and Myeloma
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, Amphista Therapeutics, AstraZeneca Pharmaceuticals LP, Be Biopharma, BeiGene Ltd, BioInvent, Bristol Myers Squibb, Deciphera Pharmaceuticals Inc, DTRM Biopharma Co Ltd, Genentech, a member of the Roche Group, InnoCare Pharma, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, Miltenyi Biomedicine, Oncternal Therapeutics, PAREXEL International Corporation, PeproMene Bio Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, BioInvent, Celgene Corporation, Genentech, a member of the Roche Group, Genmab US Inc, InnoCare Pharma, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Molecular Templates, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company, Vincerx Pharma; Honoraria: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, Bantam Pharmaceutical, BeiGene Ltd, BioInvent, Bristol Myers Squibb, DAVA Oncology, Genmab US Inc, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company; Nonrelevant Financial Relationship: Chinese American Hematologist and Oncologist Network (CAHON), Eastern Virginia Medical School, i3 Health, IDEOlogy Health, Leukemia & Lymphoma Society, MD Education, Medscape, Meeting Minds Experts, The Milken Institute, MJH Life Sciences, Moffit Cancer Center, National Institutes of Health, Physician Education Resource (PER), Practice Point Communications, OncLive, Oncology Specialty Group, Scripps MD Anderson Cancer Center, Studio ER Congressi, WebMD.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Lilly.
  
  Release date: August 2023
  Expiration date: August 2024